Peripheral cytokine release in Alzheimer patients: Correlation with disease severity

Neurobiology of Aging

Volumn 24, Issue 7, 2003, Pages 909-914

  Sala, Gessica ^a   Galimberti, Gloria ^a,b   Canevari, Carla ^a   Raggi, Maria Elisabetta ^b   Isella, Valeria ^a   Facheris, Maurizio ^a   Appollonio, Ildebrando ^a   Ferrarese, Carlo ^a,b  

^a SAN GERARDO HOSPITAL   (Italy)

^b SCIENTIFIC INSTITUTE   (Italy)

Author keywords

Alzheimer's disease; Disease severity; Inflammation; Peripheral cytokine release

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD CELL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNE SYSTEM; MALE; OBSERVATION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

EID: 0043092132     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(03)00010-1     Document Type: Article

References (33)

1. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M.et al. Inflammation and Alzheimer's disease. Neurobiol. Aging. 21(3):2000;383-421.
2. Albert S.M., Costa R., Merchant C., Small S., Jenders R.A., Stern Y. Hospitalization and Alzheimer's disease: results from a community-based study. J. Gerontol. A Biol. Sci. Med. Sci. 54(5):1999;267-271.
3. Bauer J., Strauss S., Schreiter-Gasser U., Ganter U., Sclegel P., Witt I.et al. Interleukin-6 and α-2-macroglobulin indicate an acute phase state in Alzheimer's disease cortex. FEBS Lett. 285:1991;111-114.
4. Cacabelos R., Barquero M., Garcia P., Alvarez X.A., Varela de Seijas E. Cerebrospinal fluid interleukin-1β in Alzheimer's disease and neurological disorders. Methods Find. Clin. Pharmacol. 13:1991;455-458.
5. Cagnin A., Brooks D.J., Kennedy A.M., Gunn R.N., Myers R., Turkheimer F.E. In vivo measurement of activated microglia in dementia. The Lancet. 358:2001;461-467.
6. De Luigi A., Fragiacomo C., Lucca U., Quadri P., Tettamanti M., De Simoni M.G. Inflammatory markers in Alzheimer's disease and multi-infarct dementia. Mech. Ageing Dev. 122:2001;1985-1995.
7. De Simoni M.G., Del Bo R., De Luigi A., Simard S., Forloni G. Central endotoxin induces different patterns of interleukin (IL)-1β and IL-6 messanger ribonucleic acid expression and IL-6 secretion in the brain and periphery. Endocrinology. 136:1995;897-902.
8. Delacourte A., Sergeant N., Champain D., Wattez A., Maurage C.A., Lebert F.et al. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology. 59:2002;398-407.
9. Fillit H., Ding W., Buee L., Kalman J., Altstiel L., Lawlor B.et al. Elevated circulating tumor necrosis factor in Alzheimer's disease. Neurosci. Lett. 129:1991;318-320.
10. Gitter B.D., Cox L.M., Russel R.E., May P.C. Amyloid beta peptide potentiates cytokine secretion by interleukin-1β-activated human astrocytoma cells. Proc. Natl. Acad Sci. U.S.A. 92:1995;10741-10783.
11. Graff-Radford N., Ertekin-Taner N., Jadeja N., Younkin L., Petersen R., Younkin S.et al. Evidence that plasma amyloid beta protein may be useful as a premorbid biomarker for Alzheimer's disease. Neurobiol. Aging. 23(1):2002;S384.
12. Griffin W., Stanley L.C., Ling C., White L., Macleod V., Perrot L.et al. Brain interleukin-1 and S-100 immunoreactivity elevated in Down's syndrome and Alzheimer's disease. Proc. Natl. Acad Sci. U.S.A. 86:1989;7611-7615.
13. Grimaldi L.M., Casadei V.M., Ferri C., Veglia F., Licastro F., Annoni G.et al. Association of early-onset Alzheimer's disease with an interleukin-1α gene polymorphism. Ann. Neurol. 47(3):2000;361-365.
14. Hampel H., Schoen D., Schwarz M.J., Kotter H.U., Schneider C., Sunderland T.et al. Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease. Neurosci. Lett. 228(3):1997;143-146.
15. Huberman M., Shalit F., Roth-Deri I., Gutman B., Brodie C., Kott E.et al. Correlation of cytokine secretion by mononuclear cells of Alzheimer patients and their disease stage. J. Neuroimmunol. 52:1994;147-152.
16. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF and plasma amyloid (β) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21(2):2001;372-381.
17. Licastro F., Pedrini S., Caputo L., Annoni G., Davis L.J., Ferri C.et al. Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J. Neuroimmunol. 103:2000;97-102.
18. Lombardi V.R., Garcia M., Rey L., Cacabelos R. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's disease (AD) individuals. J. Neuroimmunol. 97(1/2):1999;163-171.
19. Lorton D., Kocsis J.M., King L., Madden K., Brunden K.R. β-Amyloid induces increased release of interleukin-1β from lipopolysaccharide-activated human monocytes. J. Neuroimmunol. 67:1996;21-29.
20. McGeer P.L., Akiyama H., Itagaki S., McGeer E.G. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett. 107:1989;341-346.
21. Meda L., Cassatella M.A., Szendrei G.I., Otvos L. Jr., Baron P., Villalba M.et al. Activation of microglial cells by β-amyloid protein and interferon-γ Nature. 374:1995;647-650.
22. Monsonego A., Maron R., Zota V., Selkoe D.J., Weiner H.L. Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. PNAS. 98(18):2001;10273-10278.
23. Murialdo G., Barreca A., Nobili F., Rollero A., Timossi G., Gianelli M.V.et al. Relationships between cortisol, dehydroepiandrosterone sulphate and insulin-like growth factor-I system in dementia. J. Endocrinol. Invest. 24(3):2001;139-146.
24. Nicoll J.A., Mrak R.E., Graham D.I., Stewart J., Wilcock G., MacGowan S.et al. Association of interleukin-1 gene polymorphism with Alzheimer's disease. Ann. Neurol. 47(3):2000;365-368.
25. Papassotiropoulos A., Bagli M., Jessen F., Bayer T.A., Maier W., Rao M.L.et al. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. Ann. Neurol. 45(5):1999;666-668.
26. Rasmuson S., Nasman B., Carlstrom K., Olsson T. Increased levels of adrenocortical and gonadal hormones in mild to moderate Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 13(2):2002;74-79.
27. Song D.K., Im Y.B., Jung J.S., Cho J., Suh H.W., Kim Y.H. Central beta-amyloid peptide-induced peripheral interleukin-6 responses in mice. J. Neurochem. 76:2001;1326-1335.
28. Tamaoka A., Fukushima T., Sawamura N., Ishikawa K., Oguni E., Komatsuzaki Y.et al. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J. Neurol. Sci. 141(12):1996;65-68.
29. Tarkowski E., Blennow K., Wallin A., Tarkowski A. Intracerebral production of tumor necrosis factor-α, a local neuroprotective agent in Alzheimer disease and vascular dementia. J. Clin. Immunol. 19:1999;223-230.
30. Tarkowski E., Liljeroth A.M., Nilsson A., Ricksten A., Davidsson P., Minthon L.et al. TNF gene polymorphism and its relation to intracerebral production of TNFα and TNFβ in AD. Neurology. 54:2000;2077-2081.
31. Trieb K., Ransmayr G., Sgonc R., Lassmann H., Grubeck-Loebenstein B. APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Neurobiol. Aging. 17(4):1996;541-547.
32. Weaver J.D., Huang M.H., Albert M., Harris T., Rowe J.W., Seeman T.E. Interleukin-6 and risk of cognitive decline. Neurology. 59:2002;371-378.
33. Webster J.I., Tonelli L., Sternberg E.M. Neuroendocrine regulation of immunity. Annu. Rev. Immunol. 20:2002;125-163.